Treatment of inflammatory conditions comprising imu-856
AssigneeImmunic AG
InventorsFranziska BURIANEK, Andreas MÜHLER, Christian GEGE, Manfred GRÖPPEL, Hella KOHLHOF, Daniel VITT
Life of this patent
Estimating the term…
Abstract
The present invention relates to the sirtuin 6 (SIRT6) modulator IMU-856 or a pharmaceutically acceptable salt or solvate thereof for use in a method of preventing, treating or ameliorating inflammatory conditions, such as gastrointestinal diseases like celiac disease (CelD), comprising administering to a human a therapeutically effective amount of the SIRT6 modulator as well as the corresponding method of preventing, treating or ameliorating inflammatory conditions.
Claims12
A compound that is 6-(trans-4-(4-(trans-4-(4-methyl-5-(((4-(trifluoromethyl)pyridin-2-yl)oxy)methyl)-4H-1,2,4-triazol-3-yl)cyclohexyl)-1H-pyrazol-1-yl)cyclohexyl)-1-oxa-6-azaspiro[3.3]heptane of formula (I)
- or a pharmaceutically acceptable salt or a solvate thereof for use as a medicament for preventing, ameliorating or treating an inflammatory condition in a patient in need thereof, wherein the compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof is administered to said patient in a daily dose of about 34 to about 1370 μmol.
Dependencies are inferred from the claim text.